WO2002012447A2 - Isolation and use of solid tumor stem cells - Google Patents
Isolation and use of solid tumor stem cells Download PDFInfo
- Publication number
- WO2002012447A2 WO2002012447A2 PCT/US2001/024243 US0124243W WO0212447A2 WO 2002012447 A2 WO2002012447 A2 WO 2002012447A2 US 0124243 W US0124243 W US 0124243W WO 0212447 A2 WO0212447 A2 WO 0212447A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid tumor
- cells
- tumor stem
- stem cell
- population
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 1045
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 598
- 238000002955 isolation Methods 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 779
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 156
- 108010070047 Notch Receptors Proteins 0.000 claims abstract description 75
- 102000005650 Notch Receptors Human genes 0.000 claims abstract description 74
- 239000007924 injection Substances 0.000 claims abstract description 44
- 238000002347 injection Methods 0.000 claims abstract description 44
- 230000035755 proliferation Effects 0.000 claims abstract description 43
- 241000699670 Mus sp. Species 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims description 303
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 165
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 165
- 230000014509 gene expression Effects 0.000 claims description 140
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 133
- 102100032912 CD44 antigen Human genes 0.000 claims description 131
- 108090000623 proteins and genes Proteins 0.000 claims description 124
- 201000011510 cancer Diseases 0.000 claims description 122
- 230000000381 tumorigenic effect Effects 0.000 claims description 118
- 208000026310 Breast neoplasm Diseases 0.000 claims description 115
- 206010006187 Breast cancer Diseases 0.000 claims description 113
- 239000003550 marker Substances 0.000 claims description 87
- 238000012360 testing method Methods 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 71
- 102000040430 polynucleotide Human genes 0.000 claims description 70
- 108091033319 polynucleotide Proteins 0.000 claims description 70
- 239000002157 polynucleotide Substances 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 66
- 231100001221 nontumorigenic Toxicity 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 63
- 238000004458 analytical method Methods 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 52
- 239000000523 sample Substances 0.000 claims description 49
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 48
- 238000002493 microarray Methods 0.000 claims description 47
- 239000002458 cell surface marker Substances 0.000 claims description 43
- 238000000338 in vitro Methods 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 229920001184 polypeptide Polymers 0.000 claims description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims description 40
- 238000011579 SCID mouse model Methods 0.000 claims description 36
- 238000001727 in vivo Methods 0.000 claims description 30
- 238000000684 flow cytometry Methods 0.000 claims description 29
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 28
- 238000009396 hybridization Methods 0.000 claims description 28
- 239000003446 ligand Substances 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 25
- 206010039491 Sarcoma Diseases 0.000 claims description 25
- 239000002299 complementary DNA Substances 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 201000009030 Carcinoma Diseases 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 23
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 22
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 22
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 22
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 230000004083 survival effect Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 18
- 230000002062 proliferating effect Effects 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 17
- 238000012239 gene modification Methods 0.000 claims description 16
- 230000005017 genetic modification Effects 0.000 claims description 16
- 235000013617 genetically modified food Nutrition 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 13
- 239000006285 cell suspension Substances 0.000 claims description 11
- -1 CD31 Proteins 0.000 claims description 10
- 206010061598 Immunodeficiency Diseases 0.000 claims description 10
- 210000000577 adipose tissue Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 8
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 230000005740 tumor formation Effects 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 7
- 238000013537 high throughput screening Methods 0.000 claims description 7
- 230000004614 tumor growth Effects 0.000 claims description 7
- 239000012642 immune effector Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 210000000349 chromosome Anatomy 0.000 claims description 5
- 239000006249 magnetic particle Substances 0.000 claims description 5
- 238000011269 treatment regimen Methods 0.000 claims description 5
- 230000022131 cell cycle Effects 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 238000007619 statistical method Methods 0.000 claims description 3
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000004091 panning Methods 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 21
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 21
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 18
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 18
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 230000009918 complex formation Effects 0.000 claims 2
- 238000013480 data collection Methods 0.000 claims 2
- 238000013500 data storage Methods 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 102000014736 Notch Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 33
- 230000037361 pathway Effects 0.000 abstract description 15
- 230000003021 clonogenic effect Effects 0.000 abstract description 10
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 7
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 6
- 230000036952 cancer formation Effects 0.000 abstract description 6
- 210000005075 mammary gland Anatomy 0.000 abstract description 2
- 231100000588 tumorigenic Toxicity 0.000 description 98
- 210000001519 tissue Anatomy 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 62
- 239000003814 drug Substances 0.000 description 52
- 102100025254 Neurogenic locus notch homolog protein 4 Human genes 0.000 description 51
- 108010029741 Notch4 Receptor Proteins 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 35
- 102000053602 DNA Human genes 0.000 description 34
- 150000007523 nucleic acids Chemical group 0.000 description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 31
- 108020004635 Complementary DNA Proteins 0.000 description 31
- 229940079593 drug Drugs 0.000 description 31
- 108020004999 messenger RNA Proteins 0.000 description 30
- 238000010804 cDNA synthesis Methods 0.000 description 24
- 238000003491 array Methods 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 17
- 238000011161 development Methods 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 239000003124 biologic agent Substances 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 102100035476 Serum paraoxonase/arylesterase 1 Human genes 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 210000000481 breast Anatomy 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 238000007876 drug discovery Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000004952 protein activity Effects 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000000018 DNA microarray Methods 0.000 description 9
- 101150029707 ERBB2 gene Proteins 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 239000003596 drug target Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 238000011319 anticancer therapy Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000005757 colony formation Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 7
- 229960005420 etoposide Drugs 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000000099 in vitro assay Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 229940124650 anti-cancer therapies Drugs 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000009643 clonogenic assay Methods 0.000 description 6
- 231100000096 clonogenic assay Toxicity 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000005462 in vivo assay Methods 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 210000005170 neoplastic cell Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 206010055113 Breast cancer metastatic Diseases 0.000 description 5
- 102100025247 Neurogenic locus notch homolog protein 3 Human genes 0.000 description 5
- 108010029756 Notch3 Receptor Proteins 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000009509 drug development Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000007899 nucleic acid hybridization Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 208000002151 Pleural effusion Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 239000013545 self-assembled monolayer Substances 0.000 description 4
- 238000003196 serial analysis of gene expression Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000004565 tumor cell growth Effects 0.000 description 4
- 238000012447 xenograft mouse model Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 238000011789 NOD SCID mouse Methods 0.000 description 3
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000008195 breast development Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000012775 microarray technology Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000012583 B-27 Supplement Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000048851 human CD44 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000007798 limiting dilution analysis Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 238000001531 micro-dissection Methods 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 231100001223 noncarcinogenic Toxicity 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000002094 self assembled monolayer Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- DWAOUXYZOSPAOH-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]furo[3,2-g]chromen-7-one;hydrochloride Chemical compound [Cl-].O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC[NH+](CC)CC DWAOUXYZOSPAOH-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 238000008677 BTA stat Test Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102000007269 CA-125 Antigen Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 101100379376 Caenorhabditis elegans apx-1 gene Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- 101710112748 Delta-like protein 3 Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150098893 GEM gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101001040751 Homo sapiens Granulysin Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- XRYVAQQLDYTHCL-UHFFFAOYSA-N Marini Chemical compound O1C=2C(CC(CC=C(C)C)C(C)=C)=C(O)C=C(O)C=2C(=O)CC1C1=CC=C(O)C=C1O XRYVAQQLDYTHCL-UHFFFAOYSA-N 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 231100000264 OECD 451 Carcinogenicity Study Toxicity 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001148064 Photorhabdus luminescens Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241001363516 Plusia festucae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100022033 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100032733 Protein jagged-2 Human genes 0.000 description 1
- 101710170213 Protein jagged-2 Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010062276 T-Cell Acute Lymphocytic Leukemia Protein 1 Proteins 0.000 description 1
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000017047 asymmetric cell division Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 230000004022 gliogenesis Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 238000012036 ultra high throughput screening Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000003142 viral transduction method Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES01956101.8T ES2553796T3 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
US10/343,692 US7115360B2 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
EP01956101.8A EP1343871B1 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
JP2002517738A JP5352037B2 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
AU2001278134A AU2001278134B2 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
CA2417909A CA2417909C (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
AU7813401A AU7813401A (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
EP10179961.7A EP2359863B1 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
US11/529,869 US7850961B2 (en) | 2000-08-03 | 2006-09-29 | Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist |
US11/607,780 US7754206B2 (en) | 2000-08-03 | 2006-12-01 | Method for treating cancer using a Notch4 ligand antagonist |
US11/651,214 US20090004205A1 (en) | 2000-08-03 | 2007-01-09 | Prospective identification and characterization of breast cancer stem cells |
US11/788,489 US20080194022A1 (en) | 2000-08-03 | 2007-04-20 | Isolation and use of solid tumor stem cells |
US11/776,935 US8044259B2 (en) | 2000-08-03 | 2007-07-12 | Determining the capability of a test compound to affect solid tumor stem cells |
US12/758,540 US20110033481A1 (en) | 2000-08-03 | 2010-04-12 | Prospective identification and characterization of breast cancer stem cells |
US12/979,991 US8357491B2 (en) | 2000-08-03 | 2010-12-28 | Isolation and use of solid tumor stem cells |
US13/241,701 US8420885B2 (en) | 2000-08-03 | 2011-09-23 | Determining the capability of a test compound to affect solid tumor stem cells |
US13/563,884 US20120295350A1 (en) | 2000-08-03 | 2012-08-01 | Prospective Identification and Characterization of Breast Cancer Stem Cells |
US13/714,921 US20140011274A1 (en) | 2000-08-03 | 2012-12-14 | Isolation and use of solid tumor stem cells |
US13/795,381 US9089556B2 (en) | 2000-08-03 | 2013-03-12 | Method for treating cancer using an antibody that inhibits notch4 signaling |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22279400P | 2000-08-03 | 2000-08-03 | |
US60/222,794 | 2000-08-03 | ||
US24031700P | 2000-10-13 | 2000-10-13 | |
US60/240,317 | 2000-10-13 | ||
US09/920,517 | 2001-08-01 | ||
US09/920,517 US6984522B2 (en) | 2000-08-03 | 2001-08-01 | Isolation and use of solid tumor stem cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/920,517 Continuation US6984522B2 (en) | 2000-08-03 | 2001-08-01 | Isolation and use of solid tumor stem cells |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/343,692 A-371-Of-International US7115360B2 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
US10343692 A-371-Of-International | 2001-08-02 | ||
US11/529,869 Continuation US7850961B2 (en) | 2000-08-03 | 2006-09-29 | Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002012447A2 true WO2002012447A2 (en) | 2002-02-14 |
WO2002012447A3 WO2002012447A3 (en) | 2003-04-24 |
WO2002012447B1 WO2002012447B1 (en) | 2003-07-03 |
Family
ID=27397140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/024243 WO2002012447A2 (en) | 2000-08-03 | 2001-08-02 | Isolation and use of solid tumor stem cells |
Country Status (7)
Country | Link |
---|---|
US (13) | US6984522B2 (en) |
EP (2) | EP1343871B1 (en) |
JP (1) | JP5352037B2 (en) |
AU (2) | AU2001278134B2 (en) |
CA (1) | CA2417909C (en) |
ES (1) | ES2553796T3 (en) |
WO (1) | WO2002012447A2 (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1461023A2 (en) * | 2001-12-07 | 2004-09-29 | The Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
WO2004097008A1 (en) * | 2003-05-02 | 2004-11-11 | Cytovation As | Method of generating and isolating tumour cells |
EP1499180A2 (en) * | 2002-04-16 | 2005-01-26 | Dana-Farber Cancer Institute, Inc. | Cancer models |
WO2006047878A1 (en) * | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
WO2006051405A2 (en) * | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
JP2007516693A (en) * | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | Compositions and methods for the treatment and diagnosis of cancer |
JP2007536915A (en) * | 2004-05-12 | 2007-12-20 | ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | Cell isolation method |
EP1887860A2 (en) * | 2005-05-24 | 2008-02-20 | Centro de Investigacion Biomolecular Aplicada S.L. | Murine stem cells and applications thereof |
WO2008052740A3 (en) * | 2006-10-31 | 2008-06-26 | Fond I R C C S Istituto Neurol | Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours |
JP2009501515A (en) * | 2005-06-30 | 2009-01-22 | ホワイトヘッド・インスティチュート | Progenitor cells and uses thereof |
EP2052089A1 (en) * | 2006-07-28 | 2009-04-29 | Chundsell Medicals Ab | Embryonic stem cell markers for cancer diagnosis and prognosis |
US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
US7754206B2 (en) | 2000-08-03 | 2010-07-13 | The Regents Of The University Of Michigan | Method for treating cancer using a Notch4 ligand antagonist |
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
US7939263B2 (en) | 2005-06-13 | 2011-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
EP2318040A1 (en) * | 2008-07-24 | 2011-05-11 | University Of Central Florida Research Foundation, Inc. | Therapy targeting cancer stem cells |
US8088617B2 (en) | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
EP2404614A1 (en) * | 2006-12-20 | 2012-01-11 | Novarx | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
US8158757B2 (en) | 2007-07-02 | 2012-04-17 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8226943B2 (en) | 2008-07-08 | 2012-07-24 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
US8324361B2 (en) | 2005-10-31 | 2012-12-04 | Oncomed Pharmaceuticals, Inc. | Nucleic acid molecules encoding soluble frizzled (FZD) receptors |
US8435746B2 (en) | 2006-09-22 | 2013-05-07 | The Regents Of The University Of Michigan | Aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker |
US8507442B2 (en) | 2008-09-26 | 2013-08-13 | Oncomed Pharmaceuticals, Inc. | Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8 |
US8551789B2 (en) | 2010-04-01 | 2013-10-08 | OncoMed Pharmaceuticals | Frizzled-binding agents and their use in screening for WNT inhibitors |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US9157904B2 (en) | 2010-01-12 | 2015-10-13 | Oncomed Pharmaceuticals, Inc. | Wnt antagonists and methods of treatment and screening |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US9181333B2 (en) | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
EP2772268A4 (en) * | 2011-10-28 | 2015-12-02 | Chugai Pharmaceutical Co Ltd | Cancer stem cell-specific molecule |
US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9527921B2 (en) | 2015-04-16 | 2016-12-27 | Eisai R&D Management Co., Ltd. | Anti human Notch4 antibody |
US9850311B2 (en) | 2005-10-31 | 2017-12-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US10018630B2 (en) | 2011-09-07 | 2018-07-10 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
WO2018127055A1 (en) * | 2017-01-04 | 2018-07-12 | Yang Pan Chyr | Biomarkers for lung cancer stem cells |
US10064937B2 (en) | 2014-09-16 | 2018-09-04 | Oncomed Pharmaceuticals, Inc. | Treatment of dermal fibrosis |
CN110487998A (en) * | 2019-08-13 | 2019-11-22 | 迈克医疗电子有限公司 | Parameter optimization method and device, analysis instrument, the storage medium of magnetic separation system |
US10596179B2 (en) | 2014-05-19 | 2020-03-24 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
US10919883B2 (en) | 2012-08-09 | 2021-02-16 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
WO2021116714A1 (en) * | 2019-12-12 | 2021-06-17 | Achilles Therapeutics Uk Limited | Method for obtaining nucleic acid for sequencing |
US11124773B2 (en) | 2010-10-06 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell population and method for production thereof |
US11183269B2 (en) | 2012-10-09 | 2021-11-23 | Five3 Genomics, Llc | Systems and methods for tumor clonality analysis |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
US11524950B2 (en) | 2012-08-09 | 2022-12-13 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US11536713B2 (en) | 2009-12-25 | 2022-12-27 | Chugai Seiyaku Kabushiki Kaisha | Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
ES2375724T3 (en) | 2002-09-27 | 2012-03-05 | The General Hospital Corporation | MICROFLUDE DEVICE FOR SEPERATION OF CELLS AND ITS USES. |
US20060084599A1 (en) * | 2003-03-05 | 2006-04-20 | Maine Medical Center | Compositions, methods and kits relating to notch signaling |
US20060194315A1 (en) * | 2003-03-31 | 2006-08-31 | Condie Brian G | Compositions and methods for the control, differentiaton and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway |
US20040265281A1 (en) * | 2003-04-07 | 2004-12-30 | Denis Rodgerson | System capable of treating and defining various diseases using stem cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US7875273B2 (en) | 2004-12-23 | 2011-01-25 | Ethicon, Incorporated | Treatment of Parkinson's disease and related disorders using postpartum derived cells |
CA2530533C (en) | 2003-06-27 | 2015-02-10 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US20060223177A1 (en) | 2003-06-27 | 2006-10-05 | Ethicon Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US20050193432A1 (en) * | 2003-11-18 | 2005-09-01 | Whitehead Institute For Biomedical Research | Xenograft model of functional normal and malignant human breast tissues in rodents and methods thereof |
ATE552851T1 (en) | 2004-02-03 | 2012-04-15 | Univ Michigan | COMPOSITIONS FOR THE TREATMENT OF BREAST AND PANCREATIC CANCER |
WO2005074633A2 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
WO2005084380A2 (en) * | 2004-03-03 | 2005-09-15 | The General Hospital Corporation | System for delivering a diluted solution |
US20060121624A1 (en) * | 2004-03-03 | 2006-06-08 | Huang Lotien R | Methods and systems for fluid delivery |
US8252591B2 (en) | 2004-05-07 | 2012-08-28 | Whitehead Institute For Biomedical Research | Hormone responsive tissue culture system and uses thereof |
US8067230B2 (en) * | 2004-05-14 | 2011-11-29 | New York University | Prostatic stem cells, isolation and uses |
KR101209833B1 (en) * | 2004-06-17 | 2012-12-07 | 메사추세츠 인스티튜트 오브 테크놀로지 | Methods for identifying stem cells based on nuclear morphotypes |
US7989001B2 (en) * | 2004-09-13 | 2011-08-02 | Untae Kim | Method of separating tumor cells with and without lymphotropic metastatic potential in a human carcinoma |
ITRM20040438A1 (en) * | 2004-09-15 | 2004-12-15 | Univ Palermo | METHOD FOR PURIFICATION AND AMPLIFICATION OF CANCER STEM CELLS. |
GB0421838D0 (en) * | 2004-09-30 | 2004-11-03 | Congenia S R L | Cancer markers |
US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
US20070026418A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
NZ591701A (en) | 2005-05-16 | 2012-11-30 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
WO2007044091A2 (en) * | 2005-06-02 | 2007-04-19 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070044168A1 (en) * | 2005-07-12 | 2007-02-22 | Northwestern University | Transplantable tumor model |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
US20070059716A1 (en) * | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
US20070059719A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Business methods for prenatal Diagnosis |
JP5129149B2 (en) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Compositions and methods for treating and diagnosing cancer |
US20070220621A1 (en) * | 2005-10-31 | 2007-09-20 | Clarke Michael F | Genetic characterization and prognostic significance of cancer stem cells in cancer |
DE102005052384B4 (en) * | 2005-10-31 | 2009-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for the detection, labeling and treatment of epithelial lung tumor cells and means for carrying out the method |
EP1963490A2 (en) * | 2005-12-09 | 2008-09-03 | Massachussets Institute of Technology | Methods for identifying and targeting tumor stem cells based on nuclear morphology |
CA2630839C (en) * | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
US9175261B2 (en) | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
JP5179376B2 (en) * | 2005-12-19 | 2013-04-10 | エシコン・インコーポレイテッド | In vitro growth of postpartum-extracted cells in roller bottles |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
US20070243192A1 (en) * | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
CN101405399A (en) * | 2006-03-16 | 2009-04-08 | 健康研究股份有限公司 | Inhibition of breast carcinoma stem cell growth and metastasis |
US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
WO2007134274A2 (en) * | 2006-05-12 | 2007-11-22 | Attenuon, Llc | Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy |
EP2589668A1 (en) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Rare cell analysis using sample splitting and DNA tags |
WO2008111990A1 (en) * | 2006-06-14 | 2008-09-18 | Cellpoint Diagnostics, Inc. | Rare cell analysis using sample splitting and dna tags |
US8137912B2 (en) * | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US20080070792A1 (en) | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US7737253B2 (en) * | 2006-06-16 | 2010-06-15 | Bresagen, Inc. | Human cancer stem cell culture compositions comprising Erbb2 variants and methods of use thereof |
WO2009045201A1 (en) * | 2006-08-02 | 2009-04-09 | Biogen Idec Ma Inc. | Cancer stem cells |
EP2783700A1 (en) * | 2006-09-07 | 2014-10-01 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
US20080118432A1 (en) * | 2006-09-07 | 2008-05-22 | Ivan Bergstein | Monitoring cancer stem cells |
EP2084267B1 (en) * | 2006-09-26 | 2018-04-11 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
CA2700436C (en) | 2006-09-28 | 2017-04-18 | John S. Yu | Cancer vaccines and vaccination methods |
US8765390B2 (en) * | 2006-12-08 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of squamous carcinoma stem cells |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
WO2008091908A2 (en) * | 2007-01-22 | 2008-07-31 | Raven Biotechnologies | Human cancer stem cells |
WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
US20100255999A1 (en) * | 2007-02-01 | 2010-10-07 | Dana-Farber Cancer Institute, Inc. | Cell Co-Culture Systems and Uses Thereof |
US20090208491A1 (en) * | 2007-02-14 | 2009-08-20 | Austin Gurney | Compositions and Methods for Diagnosing and Treating Cancer |
JP5190861B2 (en) * | 2007-05-11 | 2013-04-24 | オリンパス株式会社 | Biological tissue decomposition method |
WO2008143795A1 (en) * | 2007-05-11 | 2008-11-27 | Champions Biotechnology, Inc. | Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing |
WO2008140751A1 (en) * | 2007-05-11 | 2008-11-20 | Champions Biotechnology, Inc. | Human leiosarcoma and non small cell lung cancer lung xenograft models |
EP2155249A4 (en) * | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
CN101720436A (en) * | 2007-06-13 | 2010-06-02 | 麻省理工学院 | Be used for suppressing the method and the medicament of tumor growth by the ssDNA replicative intermediate of targeting tumor stem cells |
US8642306B2 (en) * | 2007-06-14 | 2014-02-04 | Mitsui Engineering & Shipbuilding Co., Ltd. | Flow cytometer having cell-sorting function and method of separating living cells |
EP2190481B1 (en) * | 2007-07-17 | 2014-12-24 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
EP2188367A4 (en) | 2007-08-10 | 2010-10-27 | Whitehead Biomedical Inst | Hormone responsive tissue culture system and uses thereof |
EP2037265A1 (en) * | 2007-09-17 | 2009-03-18 | Adnagen AG | Solid phase cell isolation and/or enrichment method |
US20100285001A1 (en) * | 2007-10-02 | 2010-11-11 | University Of Rochester | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
JP5323845B2 (en) | 2007-10-05 | 2013-10-23 | エシコン・インコーポレイテッド | Repair and reconstruction of kidney tissue using human umbilical cord tissue-derived cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
US20110124032A1 (en) * | 2008-02-01 | 2011-05-26 | Maximilian Diehn | Methods and Compositions for Treating Carcinoma Stem Cells |
US8008032B2 (en) * | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
ES2565779T3 (en) * | 2008-09-02 | 2016-04-06 | Cedars-Sinai Medical Center | CD133 epitopes |
EP2927244A1 (en) * | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
SI2334812T1 (en) | 2008-09-20 | 2017-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Building 170 | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US20100093552A1 (en) * | 2008-10-09 | 2010-04-15 | Asit Panja | Use and identification of biomarkers for gastrointestinal diseases |
CN102224241B (en) * | 2008-10-24 | 2015-02-18 | 洛杉矶儿童医院 | Amniotic fluid cells and uses thereof |
NZ602369A (en) | 2008-11-11 | 2015-02-27 | Univ Michigan | Anti-cxcr1 compositions and methods |
WO2010071864A1 (en) | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Treatment of lung and pulmonary diseases and disorders |
US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
EP2401362B1 (en) | 2009-02-26 | 2017-04-12 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of renal stem cells and methods of isolating and using same |
US8170320B2 (en) | 2009-03-03 | 2012-05-01 | Hologic, Inc. | Mammography/tomosynthesis systems and methods automatically deriving breast characteristics from breast x-ray images and automatically adjusting image processing parameters accordingly |
US8762069B2 (en) * | 2009-03-11 | 2014-06-24 | Institute for Medical Biomathematics | Therapeutic implications of dickkopf affecting cancer stem cell fate |
BRPI1013409A2 (en) | 2009-03-26 | 2018-01-16 | Advanced Tech And Regenerative Medicine Llc | human umbilical cord tissue cells as therapy for alzheimer's disease |
DK2427485T3 (en) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | CD133 epitopes |
JP2013509882A (en) * | 2009-11-05 | 2013-03-21 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Catena: Serous cancer stem cells |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
CA2782299A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
US20110312503A1 (en) | 2010-01-23 | 2011-12-22 | Artemis Health, Inc. | Methods of fetal abnormality detection |
EP2529238A4 (en) | 2010-01-28 | 2014-10-08 | The Regents Of The University Of Michigan | Hanging drop devices, systems and/or methods |
CA2806127C (en) | 2010-07-23 | 2021-12-21 | Advanced Cell Technology, Inc. | Methods for detection of rare subpopulations of cells and highly purified compositions of cells |
EP2611463A2 (en) | 2010-09-03 | 2013-07-10 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
WO2012044979A2 (en) | 2010-10-01 | 2012-04-05 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Manipulation of stem cell function by p53 isoforms |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
JP2013540276A (en) | 2010-10-25 | 2013-10-31 | マサチューセッツ インスティテュート オブ テクノロジー | Metakaryotic stem cells that heal wounds and methods of use thereof |
US8912156B1 (en) | 2011-02-04 | 2014-12-16 | Whitehead Institute For Biomedical Research | Markers for and methods of targeting tumor stem cells |
WO2012167101A1 (en) | 2011-06-03 | 2012-12-06 | The General Hospital Corporation | Ovarian cancer stem cells and methods of isolation and uses thereof |
US9663573B2 (en) | 2011-10-05 | 2017-05-30 | Genentech, Inc. | Methods of treating liver conditions using Notch2 antagonists |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
BR112014015424A2 (en) | 2011-12-23 | 2018-05-22 | Depuy Synthes Products Llc | detection of cells derived from human umbilical cord tissue |
DK2817620T3 (en) * | 2012-02-22 | 2016-09-05 | Verik Bio Inc | IMMUNTERY TREATMENT SYSTEM FOR TUMOR FORMATION AND PROGRESSION |
US20140147861A1 (en) * | 2012-05-04 | 2014-05-29 | The Regents of the University of Califomia | Markers to identify primary cells from tumor biopsies |
EP2852682B1 (en) | 2012-05-21 | 2017-10-04 | Fluidigm Corporation | Single-particle analysis of particle populations |
WO2014028446A1 (en) | 2012-08-13 | 2014-02-20 | Genentech, Inc. | Anti-jagged anitbodies and methods of use |
US20160017293A1 (en) * | 2012-08-15 | 2016-01-21 | Neostem Oncology, Llc | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
AU2013303012B2 (en) * | 2012-08-15 | 2017-04-27 | Neostem Oncology, Llc | Rapid method production high purity cancer stem cells and population of high purity cancer stem cells |
WO2014062921A1 (en) * | 2012-10-19 | 2014-04-24 | Interdigital Patent Holdings, Inc. | Multi-hypothesis rate adaptation for http streaming |
US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
CA2898474A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
EP2968408A4 (en) * | 2013-03-11 | 2016-11-23 | Neostem Oncology Llc | Method of induction and purification of a cell population responsible for vasculary mimicry and use of the same |
AU2014248713A1 (en) * | 2013-03-12 | 2015-09-10 | Neostem Oncology, Llc | Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response |
JP6527132B2 (en) | 2013-03-15 | 2019-06-05 | ジェネンテック, インコーポレイテッド | Compositions and methods for diagnosis and treatment of liver cancer |
EP3049155A1 (en) * | 2013-09-27 | 2016-08-03 | Vaccinogen International Partners, LP | Autologous tumor vaccines and methods |
CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
IN2014MU00173A (en) * | 2014-01-20 | 2015-08-28 | Nat Ct For Cell Science | |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
JP6783143B2 (en) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | Passive replenishment of medium |
EP3161480B1 (en) | 2014-06-25 | 2020-02-12 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Identification of cancer stem cell markers and use of same for diagnosis and treatment |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
JP7393945B2 (en) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | cell proliferation |
JP2021534785A (en) | 2018-08-28 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Methods and Compositions for Adoptive T Cell Therapy Using Induced Notch Signaling |
RU2735982C2 (en) * | 2020-06-02 | 2020-11-11 | Федеральное государственное бюджетное учреждение | Method for prediction of radiosensitivity of malignant growths of upper respiratory tract |
WO2023225352A2 (en) * | 2022-05-20 | 2023-11-23 | Helex Inc. | Methods for assessment of effects of gene editing |
Family Cites Families (306)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4089003A (en) * | 1977-02-07 | 1978-05-09 | Motorola, Inc. | Multifrequency microstrip antenna |
US4109496A (en) * | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
US4323546A (en) * | 1978-05-22 | 1982-04-06 | Nuc Med Inc. | Method and composition for cancer detection in humans |
US4411990A (en) | 1979-06-13 | 1983-10-25 | University Patents, Inc. | Primary bioassay of human tumor stem cells |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4584268A (en) | 1981-10-13 | 1986-04-22 | Ceriani Roberto Luis | Method and compositions for carcinoma diagnosis |
US4612282A (en) * | 1981-12-15 | 1986-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibodies reactive with human breast cancer |
US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4960716A (en) | 1984-05-01 | 1990-10-02 | Ciba Corning Diagnostics Corp. | Monoclonal antibodies specific for 330 KD breast tumor antigen and assay using said monoclonal antibodies |
US5019497A (en) * | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4751177A (en) | 1985-06-13 | 1988-06-14 | Amgen | Methods and kits for performing nucleic acid hybridization assays |
EP0228075B1 (en) | 1986-01-03 | 1991-04-03 | Molecular Diagnostics, Inc. | Eucaryotic genomic dna dot-blot hybridization method |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4877745A (en) | 1986-11-17 | 1989-10-31 | Abbott Laboratories | Apparatus and process for reagent fluid dispensing and printing |
GB2198290B (en) * | 1986-11-29 | 1990-05-09 | Stc Plc | Dual band circularly polarised antenna with hemispherical coverage |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5087570A (en) | 1988-05-10 | 1992-02-11 | Weissman Irving L | Homogeneous mammalian hematopoietic stem cell composition |
US4981785A (en) * | 1988-06-06 | 1991-01-01 | Ventrex Laboratories, Inc. | Apparatus and method for performing immunoassays |
US4968103A (en) * | 1988-07-22 | 1990-11-06 | Photofinish Cosmetics Inc. | Method of making a brush |
WO1990001564A1 (en) | 1988-08-09 | 1990-02-22 | Microprobe Corporation | Methods for multiple target analyses through nucleic acid hybridization |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5994617A (en) | 1988-09-19 | 1999-11-30 | Hsc Research Development Corporation | Engraftment of immune-deficient mice with human cells |
CA1335181C (en) | 1988-10-11 | 1995-04-11 | R. Alan Hardwick | System for selective cell separation from cell concentrate |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
DE68919715T2 (en) | 1988-12-28 | 1995-04-06 | Stefan Miltenyi | METHOD AND MATERIALS FOR HIGHLY GRADUATED MAGNETIC SPLITTING OF BIOLOGICAL MATERIALS. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
US5219726A (en) | 1989-06-02 | 1993-06-15 | The Salk Institute For Biological Studies | Physical mapping of complex genomes |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
US6583115B1 (en) | 1989-10-12 | 2003-06-24 | Ohio University/Edison Biotechnology Institute | Methods for treating acromegaly and giantism with growth hormone antagonists |
JP2802518B2 (en) * | 1989-10-13 | 1998-09-24 | 戸田工業株式会社 | Magnetic recording media |
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5614396A (en) * | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5489677A (en) * | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5602240A (en) * | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2246502T3 (en) * | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
ES2113940T3 (en) * | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
EP0562025B1 (en) | 1990-12-06 | 2001-02-07 | Affymetrix, Inc. (a Delaware Corporation) | Compounds and their use in a binary synthesis strategy |
DE69132843T2 (en) | 1990-12-06 | 2002-09-12 | Affymetrix Inc N D Ges D Staat | Identification of nucleic acids in samples |
DE4039677A1 (en) | 1990-12-12 | 1992-06-17 | Boehringer Mannheim Gmbh | UNIVERSAL BINDING FILM |
IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human notch and delta, binding domains in toporythmic proteins, and methods based thereon |
IE20030749A1 (en) * | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
US5856441A (en) * | 1991-05-03 | 1999-01-05 | Yale University | Serrate fragments and derivatives |
US6429186B1 (en) | 1991-05-10 | 2002-08-06 | Genentech, Inc. | Ligand antagonists for treatment of breast cancer |
DE69231467T2 (en) | 1991-05-10 | 2001-01-25 | Genentech Inc | SELECTION OF AGONISTS AND ANTAGONISTS OF LIGANDS |
US5714331A (en) * | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
ES2136092T3 (en) * | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
WO1993006239A1 (en) | 1991-09-24 | 1993-04-01 | Keygene N.V. | Selective restriction fragment amplification: a general method for dna fingerprinting |
US5753229A (en) * | 1991-09-25 | 1998-05-19 | Mordoh; Jose | Monoclonal antibodies reactive with tumor proliferating cells |
DE69231853T2 (en) * | 1991-11-07 | 2001-09-13 | Nanotronics Inc | HYBRIDIZING POLYNUCLEOTIDS CONJUGED WITH CHROMOPHORES AND FLUOROPHORS TO GENERATE A DONOR-TO-DONOR ENERGY TRANSFER SYSTEM |
US5605662A (en) | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US6353150B1 (en) | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
US6004924A (en) * | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
US5869282A (en) * | 1991-12-11 | 1999-02-09 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of the serrate gene and methods based thereon |
EP0552108B1 (en) * | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
US5376313A (en) * | 1992-03-27 | 1994-12-27 | Abbott Laboratories | Injection molding a plastic assay cuvette having low birefringence |
US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US20050112121A1 (en) | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5840484A (en) | 1992-07-17 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Comparative gene transcript analysis |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
US5654183A (en) | 1992-07-27 | 1997-08-05 | California Institute Of Technology | Genetically engineered mammalian neural crest stem cells |
US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
US5928947A (en) | 1992-07-27 | 1999-07-27 | California Institute Of Technology | Mammalian multipotent neural stem cells |
JPH08500245A (en) | 1992-07-27 | 1996-01-16 | カリフォルニア インスティテュート オブ テクノロジー | Mammalian pluripotent neural stem cells |
CA2148252C (en) | 1992-10-30 | 2007-06-12 | Roger Brent | Interaction trap system for isolating novel proteins |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
JP3106021B2 (en) * | 1992-11-30 | 2000-11-06 | キヤノン株式会社 | Pattern data compression method and apparatus and output method and apparatus |
WO1994018987A1 (en) * | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Drug composition containing nucleic acid copolymer |
US5639606A (en) * | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US5643765A (en) * | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US5876978A (en) * | 1993-04-06 | 1999-03-02 | Medical College Of Ohio | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
US5744306A (en) | 1993-04-19 | 1998-04-28 | Emory University | Methods for nucleic acid detection, sequencing, and cloning using exonuclease |
US5681860A (en) | 1993-09-21 | 1997-10-28 | The Trustees Of Columbia University In The City Of New York | Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol |
US5674694A (en) | 1993-09-21 | 1997-10-07 | Biologic & Immunologic Science Laboratories, Inc. | Clonogenic assay for detecting micro levels of tumor cells in hematopoietic samples |
JPH09507121A (en) | 1993-10-26 | 1997-07-22 | アフィマックス テクノロジーズ ナームロゼ ベノートスハップ | Nucleic acid probe array on biological chip |
US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
US5599677A (en) * | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
US5654419A (en) | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
ATE336587T1 (en) * | 1994-06-10 | 2006-09-15 | Genvec Inc | ADENOVIRUS VECTOR SYSTEMS AND CELL LINES |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US6156305A (en) | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
US5710000A (en) | 1994-09-16 | 1998-01-20 | Affymetrix, Inc. | Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping |
US5650317A (en) | 1994-09-16 | 1997-07-22 | Michigan State University | Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics |
US5567326A (en) | 1994-09-19 | 1996-10-22 | Promega Corporation | Multisample magnetic separation device |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
CA2203809C (en) * | 1994-10-28 | 2008-06-03 | James M. Wilson | Recombinant adenovirus and methods of use thereof |
US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6090822A (en) * | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5821108A (en) | 1995-04-07 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker |
EP0826034A4 (en) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | Generation of large genomic dna deletions |
US5610620A (en) * | 1995-05-19 | 1997-03-11 | Comant Industries, Inc. | Combination antenna |
US5753439A (en) | 1995-05-19 | 1998-05-19 | Trustees Of Boston University | Nucleic acid detection methods |
AU6261696A (en) * | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
DE69633565T3 (en) * | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY |
US6117985A (en) * | 1995-06-16 | 2000-09-12 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched cell preparations |
ES2334953T3 (en) | 1995-06-28 | 2010-03-17 | Imperial Cancer Research Technology Limited | SEQUENCES OF NUCLEOTIDES AND PROTEINS OF DELTA GENES OF VERTEBRATES AND METHODS BASED ON THE SAME. |
US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
ATE455171T1 (en) * | 1995-09-21 | 2010-01-15 | Genentech Inc | VARIANTS OF HUMAN GROWTH HORMONE |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
US5986170A (en) * | 1995-11-13 | 1999-11-16 | Corixa Corporation | Murine model for human carcinoma |
DE19681033D2 (en) * | 1995-11-16 | 1999-03-18 | Michael W Dahm | Method for the quantification of tumor cells in a body fluid and suitable test kits |
JP4283891B2 (en) | 1995-11-17 | 2009-06-24 | 旭化成株式会社 | Differentiation-inhibiting polypeptide |
US5598677A (en) * | 1995-12-19 | 1997-02-04 | Rehm, Iii; Frederick G. | Insulated covering for building sheathing |
CA2239957A1 (en) * | 1995-12-22 | 1997-07-03 | Abbott Laboratories | Fluorescence polarization immunoassay diagnostic method |
US5720722A (en) * | 1996-01-11 | 1998-02-24 | Medela, Incorporated | Connector for use in single and double breast pumping and breast pump using same |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE69713336T2 (en) | 1996-03-30 | 2002-12-05 | Science Park Raf S P A | Process for the production of activated labeled tumor-specific T cells and their use in the treatment of tumors |
US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
AU720890B2 (en) | 1996-05-31 | 2000-06-15 | National American Red Cross, The | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
US5928638A (en) | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
US5885529A (en) * | 1996-06-28 | 1999-03-23 | Dpc Cirrus, Inc. | Automated immunoassay analyzer |
FR2751986B1 (en) | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | GENE INVOLVED IN CADASIL, DIAGNOSTIC METHOD AND THERAPEUTIC APPLICATION |
JP2000517185A (en) * | 1996-08-29 | 2000-12-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Novel metalloprotease family KUZ |
BR9712988A (en) | 1996-10-11 | 2000-10-24 | Univ California | Cancer immunotherapy using tumor cells combined with lymphocyte mixture |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US5994132A (en) * | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
US5859535A (en) * | 1997-02-12 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | System for determining size and location of defects in material by use of microwave radiation |
SE508356C2 (en) * | 1997-02-24 | 1998-09-28 | Ericsson Telefon Ab L M | Antenna Installations |
US6165709A (en) | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
CA2283267A1 (en) * | 1997-03-07 | 1998-09-11 | Clare Chemical Research Llc | Fluorometric detection using visible light |
US6080912A (en) * | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
US20030180784A1 (en) | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
EP0972041B2 (en) | 1997-04-04 | 2017-01-18 | Millennium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
DE19715484A1 (en) | 1997-04-14 | 1998-10-15 | Boehringer Mannheim Gmbh | Procedure for applying reagent spots |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US5830730A (en) * | 1997-05-08 | 1998-11-03 | The Regents Of The University Of California | Enhanced adenovirus-assisted transfection composition and method |
US5894869A (en) * | 1997-05-12 | 1999-04-20 | Crosman Corporation | CO2 cartridge pressurization device |
JP4171528B2 (en) | 1997-05-14 | 2008-10-22 | 旭化成株式会社 | Novel differentiation inhibitor |
AU8162898A (en) | 1997-06-18 | 1999-01-04 | Trustees Of Columbia University In The City Of New York, The | Angiogenic modulation by notch signal transduction |
US6379925B1 (en) | 1997-06-18 | 2002-04-30 | The Trustees Of Columbia University In The City Of New York | Angiogenic modulation by notch signal transduction |
US6136952A (en) | 1997-06-25 | 2000-10-24 | University Of Washington | Human jagged polypeptide, encoding nucleic acids and methods of use |
AU756549B2 (en) | 1997-07-11 | 2003-01-16 | Crucell Holland B.V. | Interleukin-3 gene therapy for cancer |
US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
AU748226B2 (en) | 1997-10-31 | 2002-05-30 | Applera Corporation | Method and apparatus for making arrays |
US6197523B1 (en) * | 1997-11-24 | 2001-03-06 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6183968B1 (en) | 1998-03-27 | 2001-02-06 | Incyte Pharmaceuticals, Inc. | Composition for the detection of genes encoding receptors and proteins associated with cell proliferation |
US5981225A (en) * | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US5965352A (en) | 1998-05-08 | 1999-10-12 | Rosetta Inpharmatics, Inc. | Methods for identifying pathways of drug action |
US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
JP2002523018A (en) | 1998-07-27 | 2002-07-30 | アムジエン・インコーポレーテツド | Delta-related polypeptide |
MXPA01001727A (en) | 1998-08-14 | 2001-11-27 | Aventis Pharm Prod Inc | Adenovirus formulations for gene therapy. |
CA2341061A1 (en) | 1998-08-27 | 2000-03-09 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
GB9819681D0 (en) | 1998-09-09 | 1998-11-04 | Smithkline Beecham Plc | Novel compounds |
US6146830A (en) | 1998-09-23 | 2000-11-14 | Rosetta Inpharmatics, Inc. | Method for determining the presence of a number of primary targets of a drug |
WO2000020576A2 (en) * | 1998-10-02 | 2000-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health | Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
DE69939327D1 (en) | 1998-11-02 | 2008-09-25 | Curis Inc | FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
US6610484B1 (en) | 1999-01-26 | 2003-08-26 | Cytyc Health Corporation | Identifying material from a breast duct |
US6215894B1 (en) | 1999-02-26 | 2001-04-10 | General Scanning, Incorporated | Automatic imaging and analysis of microarray biochips |
IL139321A0 (en) | 1999-03-03 | 2001-11-25 | Biogen Inc | Methods and compositions for modulating lipid metabolism |
US20030003572A1 (en) | 1999-03-05 | 2003-01-02 | David J. Anderson | Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression |
US20030119029A1 (en) | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
CA2375700A1 (en) | 1999-06-01 | 2000-12-07 | Biogen, Inc. | Polymer conjugates of hedgehog proteins and uses |
US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
EP2228446A1 (en) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
AU2000226035A1 (en) | 2000-01-10 | 2001-07-24 | Cd Warehouse, Inc. | Method and apparatus for arranging for sales using centralized ordering and decentralized shipping |
US20040048249A1 (en) | 2000-01-21 | 2004-03-11 | Tang Y. Tom | Novel nucleic acids and secreted polypeptides |
JP2003520266A (en) | 2000-01-24 | 2003-07-02 | メルク シャープ エンド ドーム リミテッド | γ-secretase inhibitor |
GB0005251D0 (en) | 2000-03-03 | 2000-04-26 | Merck Sharp & Dohme | Therapeutic compounds |
US20050070578A1 (en) | 2000-03-30 | 2005-03-31 | Baxter Anthony David | Small organic molecule regulators of cell proliferation |
US7115653B2 (en) | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US7060436B2 (en) | 2000-06-17 | 2006-06-13 | Third Wave Technologies, Inc. | Nucleic acid accessible hybridization sites |
WO2001098354A2 (en) | 2000-06-21 | 2001-12-27 | Incyte Genomics, Inc. | Human receptors |
US6632620B1 (en) * | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
DE10031380A1 (en) | 2000-06-28 | 2002-01-10 | Merck Patent Gmbh | Process for the transfer of alkylidene groups to organic compounds |
GB0016681D0 (en) | 2000-07-06 | 2000-08-23 | Merck Sharp & Dohme | Therapeutic compounds |
US7118853B2 (en) | 2000-07-26 | 2006-10-10 | Applied Genomics, Inc. | Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
WO2002018544A2 (en) | 2000-08-31 | 2002-03-07 | Loyola University Chicago | Method and reagents for treatment of skin disorders by modulating the notch pathway |
US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
AU2002211359A1 (en) | 2000-10-04 | 2002-04-15 | Ca*Tx, Inc. | Stem cell-based methods for preventing and treating tumor |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
US20020169300A1 (en) | 2001-01-30 | 2002-11-14 | Waterman Marian L. | Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 |
US7413873B2 (en) | 2001-01-30 | 2008-08-19 | The Regents Of The University Of California | Method of detection and treatment of colon cancer |
US20030064384A1 (en) | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
AU2002308557A1 (en) | 2001-05-01 | 2002-11-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
EP1401431A4 (en) | 2001-06-15 | 2004-07-07 | Genentech Inc | Human growth hormone antagonists |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
US20040023244A1 (en) | 2001-06-21 | 2004-02-05 | Griffin Jennifer A | Receptors |
ES2292772T3 (en) * | 2001-06-22 | 2008-03-16 | Stemcells, Inc. | LIVER GRAFT CELLS, ANALYSIS, AND ITS USES. |
WO2003000893A2 (en) | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Nucleic acids encoding g protein-coupled receptors |
CN1525859B (en) | 2001-07-02 | 2010-05-05 | 辛南·塔斯 | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
EP1411938B1 (en) | 2001-07-02 | 2005-07-06 | Tas, Sinan | Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
AU2002317105A1 (en) | 2001-07-05 | 2003-01-21 | University Of British Columbia | Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors |
JP2004536877A (en) | 2001-07-25 | 2004-12-09 | ロランティス リミテッド | Notch signaling modulators for immunotherapy |
BR0211513A (en) | 2001-07-27 | 2005-08-30 | Curis Inc | Hedgehog signaling pathway mediators, compositions and related uses |
US7122675B2 (en) | 2001-08-03 | 2006-10-17 | Schering Corporation | Gamma secretase inhibitors |
KR20040019094A (en) | 2001-08-03 | 2004-03-04 | 쉐링 코포레이션 | Novel gamma secretase inhibitors |
US20050137130A1 (en) | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
EP1448599A2 (en) | 2001-11-14 | 2004-08-25 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
AU2002352967A1 (en) | 2001-11-29 | 2003-06-10 | The Trustees Of Princeton University | Increased emission efficiency in organic light-emitting devices on high-index substrates |
CA2469204A1 (en) | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
WO2003060108A1 (en) | 2002-01-17 | 2003-07-24 | Københavns Universitet | A suprabasal breast cell line with stem cell properties |
GB0201674D0 (en) | 2002-01-25 | 2002-03-13 | Lorantis Ltd | Medical treatment |
US20050089896A1 (en) | 2003-02-18 | 2005-04-28 | Roy Frans V. | Method to control tumor progression and invasiveness |
US20030185829A1 (en) | 2002-03-12 | 2003-10-02 | Erich Koller | Jagged 2 inhibitors for inducing apoptosis |
EP2258872B1 (en) | 2002-03-13 | 2013-08-14 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
EP1496905B1 (en) | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
JP2005530856A (en) | 2002-06-21 | 2005-10-13 | ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | Membrane-related tumor endothelial marker |
GB0218879D0 (en) | 2002-08-14 | 2002-09-25 | Lorantis Ltd | Medical treatment |
US7803370B2 (en) | 2002-08-30 | 2010-09-28 | Oncotherapy Science, Inc. | Method for treating synovial sarcoma |
JP2006515177A (en) | 2002-09-10 | 2006-05-25 | ロランティス リミテッド | Pharmaceutical composition comprising Notch ligand protein and medical treatment |
GB0221952D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Forschungsstiftung | Wnt mediated ErbB1 signalling,compositions and uses related thereto |
US20040247593A1 (en) | 2002-10-04 | 2004-12-09 | Regents Of The University Of California, | Methods for treating cancer by inhibiting Wnt signaling |
WO2004041170A2 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
WO2004073657A2 (en) | 2003-02-19 | 2004-09-02 | Protein Design Labs, Inc. | Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
EP2233926A3 (en) | 2003-04-01 | 2011-01-12 | The Johns Hopkins University | Breast Endothelial Cell Expression Patterns |
WO2004097030A2 (en) | 2003-04-28 | 2004-11-11 | Bristol-Myers Squibb Company | Prognostic breast cancer biomarkers |
EP1627081A4 (en) | 2003-05-02 | 2006-08-16 | Health Research Inc | Use of jag2 expression in diagnosis of plasma cell disorders |
EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | Compositions and methods for treating and diagnosing cancer |
GB0321805D0 (en) | 2003-09-18 | 2003-10-15 | Univ Wales Medicine | Human tumour growth patterns |
US6894522B2 (en) * | 2003-10-06 | 2005-05-17 | International Business Machines Corporation | Specific site backside underlaying and micromasking method for electrical characterization of semiconductor devices |
WO2005074633A2 (en) | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20050221476A1 (en) | 2004-03-18 | 2005-10-06 | Arindom Sen | Chemical dissociation of cell aggregates |
CA2566549C (en) | 2004-05-12 | 2014-01-14 | The Walter And Eliza Hall Institute Of Medical Research | A method for isolating mammary stem cells |
JP2007536938A (en) | 2004-05-14 | 2007-12-20 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA |
CN102241727B (en) | 2004-08-27 | 2015-03-25 | 无限药品股份有限公司 | Cyclopamine analogues and methods of use thereof |
EP1786906A2 (en) | 2004-09-09 | 2007-05-23 | Exonhit Therapeutics SA | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis |
GB0421838D0 (en) | 2004-09-30 | 2004-11-03 | Congenia S R L | Cancer markers |
US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
JP2008519829A (en) | 2004-11-10 | 2008-06-12 | ヒュブレヒト ラボラトリウム | Treatment of intestinal adenoma and / or adenocarcinoma by inhibition of Notch pathway activation |
AU2006259583A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070220621A1 (en) | 2005-10-31 | 2007-09-20 | Clarke Michael F | Genetic characterization and prognostic significance of cancer stem cells in cancer |
JP5129149B2 (en) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Compositions and methods for treating and diagnosing cancer |
US7714014B2 (en) | 2005-12-09 | 2010-05-11 | The Regents Of The University Of California | Targeting GLI proteins in human cancer by small molecules |
CA2630839C (en) * | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
US20070243192A1 (en) | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
US20080019961A1 (en) | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
US20080241150A1 (en) | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
CA2654304A1 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
US20080187938A1 (en) | 2006-09-22 | 2008-08-07 | The Regents Of The University Of Michigan | ALDH1 As A Cancer Stem Cell Marker |
BRPI0715989A8 (en) | 2006-10-19 | 2018-03-13 | Genentech Inc | "heavy chain variable sequence (" vh "), vh chain region, light chain variable (" vl ") sequences, vl chain region, vh chain sequences, nucleic acids, vector, cell, antibodies or antibody fragments, antibodies, method for antibody production, use of an antibody, notch3 binding epitopes, composition and use of the composition " |
WO2008048680A2 (en) | 2006-10-19 | 2008-04-24 | Maine Medical Center Research Institute | Notch 2 signaling as a breast cancer suppressor pathway |
ITRM20060583A1 (en) | 2006-10-27 | 2008-04-28 | Francesco Bistoni | USE OF THE TIMAMA ALFA 1 FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND CARE OF ALLERGIES |
US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
RU2448979C2 (en) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies to delta-like human ligand-4 |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
EP2125013A4 (en) | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | Dll4 signaling inhibitors and uses thereof |
JP2010520280A (en) | 2007-03-05 | 2010-06-10 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | Negative genetic control of cancer cell regeneration with synergy with Notch or Num specific immunotherapy |
GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
PE20090321A1 (en) * | 2007-06-04 | 2009-04-20 | Genentech Inc | ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION |
EP2182958A1 (en) | 2007-07-25 | 2010-05-12 | Alma Mater Studiorum -Universita' di Bologna | Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
SG183763A1 (en) | 2007-08-23 | 2012-09-27 | Univ Columbia | Compositions of humanized notch fusion proteins and methods of treatment |
WO2009035522A1 (en) | 2007-09-14 | 2009-03-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
WO2009075565A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
MY155603A (en) * | 2008-07-08 | 2015-11-13 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
-
2001
- 2001-08-01 US US09/920,517 patent/US6984522B2/en not_active Expired - Lifetime
- 2001-08-02 CA CA2417909A patent/CA2417909C/en not_active Expired - Fee Related
- 2001-08-02 US US10/343,692 patent/US7115360B2/en not_active Expired - Lifetime
- 2001-08-02 JP JP2002517738A patent/JP5352037B2/en not_active Expired - Fee Related
- 2001-08-02 EP EP01956101.8A patent/EP1343871B1/en not_active Expired - Lifetime
- 2001-08-02 AU AU2001278134A patent/AU2001278134B2/en not_active Ceased
- 2001-08-02 WO PCT/US2001/024243 patent/WO2002012447A2/en active Application Filing
- 2001-08-02 AU AU7813401A patent/AU7813401A/en active Pending
- 2001-08-02 EP EP10179961.7A patent/EP2359863B1/en not_active Expired - Lifetime
- 2001-08-02 ES ES01956101.8T patent/ES2553796T3/en not_active Expired - Lifetime
-
2005
- 2005-06-10 US US11/150,524 patent/US9492538B2/en not_active Expired - Fee Related
- 2005-06-10 US US11/150,073 patent/US20060051325A1/en not_active Abandoned
-
2006
- 2006-09-29 US US11/529,869 patent/US7850961B2/en not_active Expired - Fee Related
- 2006-12-01 US US11/607,780 patent/US7754206B2/en not_active Expired - Fee Related
- 2006-12-28 US US11/647,006 patent/US20070212737A1/en not_active Abandoned
-
2007
- 2007-01-09 US US11/651,214 patent/US20090004205A1/en not_active Abandoned
- 2007-05-24 US US11/753,191 patent/US7713710B2/en not_active Expired - Fee Related
-
2010
- 2010-04-12 US US12/758,540 patent/US20110033481A1/en not_active Abandoned
-
2012
- 2012-08-01 US US13/563,884 patent/US20120295350A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/795,381 patent/US9089556B2/en not_active Expired - Fee Related
-
2016
- 2016-09-07 US US15/258,419 patent/US10227567B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1343871A2 |
Cited By (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754206B2 (en) | 2000-08-03 | 2010-07-13 | The Regents Of The University Of Michigan | Method for treating cancer using a Notch4 ligand antagonist |
US9089556B2 (en) | 2000-08-03 | 2015-07-28 | The Regents Of The University Of Michigan | Method for treating cancer using an antibody that inhibits notch4 signaling |
EP1461023A2 (en) * | 2001-12-07 | 2004-09-29 | The Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
EP1461023A4 (en) * | 2001-12-07 | 2005-08-31 | Univ Michigan | Prospective identification and characterization of breast cancer stem cells |
EP1499180A4 (en) * | 2002-04-16 | 2006-09-13 | Dana Farber Cancer Inst Inc | Cancer models |
EP1499180A2 (en) * | 2002-04-16 | 2005-01-26 | Dana-Farber Cancer Institute, Inc. | Cancer models |
WO2004097008A1 (en) * | 2003-05-02 | 2004-11-11 | Cytovation As | Method of generating and isolating tumour cells |
JP2007516693A (en) * | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | Compositions and methods for the treatment and diagnosis of cancer |
EP2003196A2 (en) | 2003-06-09 | 2008-12-17 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
JP2007536915A (en) * | 2004-05-12 | 2007-12-20 | ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | Cell isolation method |
WO2006047878A1 (en) * | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
WO2006051405A2 (en) * | 2004-11-12 | 2006-05-18 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
WO2006051405A3 (en) * | 2004-11-12 | 2006-10-19 | Univ Cambridge Tech | Methods and means related to cancer stem cells |
US10538742B2 (en) | 2004-11-12 | 2020-01-21 | Cambridge Enterprise Limited | Methods and means related to cancer stem cells |
EP1887860A2 (en) * | 2005-05-24 | 2008-02-20 | Centro de Investigacion Biomolecular Aplicada S.L. | Murine stem cells and applications thereof |
US7939263B2 (en) | 2005-06-13 | 2011-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US9212347B2 (en) | 2005-06-30 | 2015-12-15 | Whitehead Institute | Progenitor cells and uses thereof |
JP2009501515A (en) * | 2005-06-30 | 2009-01-22 | ホワイトヘッド・インスティチュート | Progenitor cells and uses thereof |
US9850311B2 (en) | 2005-10-31 | 2017-12-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8765913B2 (en) | 2005-10-31 | 2014-07-01 | Oncomed Pharmaceuticals, Inc. | Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells |
US9732139B2 (en) | 2005-10-31 | 2017-08-15 | Oncomed Pharmaceuticals, Inc. | Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor |
US9228013B2 (en) | 2005-10-31 | 2016-01-05 | OncoMed Pharmaceuticals | Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell |
US8324361B2 (en) | 2005-10-31 | 2012-12-04 | Oncomed Pharmaceuticals, Inc. | Nucleic acid molecules encoding soluble frizzled (FZD) receptors |
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
US8784811B2 (en) | 2006-06-13 | 2014-07-22 | Oncomed Pharmaceuticals, Inc. | Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1 |
US8404237B2 (en) | 2006-06-13 | 2013-03-26 | OncoMed Pharamaceuticals, Inc. | Antibodies to the NOTCH1 receptor |
US8206713B2 (en) | 2006-06-13 | 2012-06-26 | Oncomed Pharmaceuticals, Inc. | Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2 |
US9676865B2 (en) | 2006-06-13 | 2017-06-13 | Oncomed Pharmaceuticals, Inc. | Antibodies to a non-ligand binding region of at least two NOTCH receptors |
EP2052089A1 (en) * | 2006-07-28 | 2009-04-29 | Chundsell Medicals Ab | Embryonic stem cell markers for cancer diagnosis and prognosis |
EP2052089A4 (en) * | 2006-07-28 | 2010-05-05 | Chundsell Medicals Ab | Embryonic stem cell markers for cancer diagnosis and prognosis |
US8435746B2 (en) | 2006-09-22 | 2013-05-07 | The Regents Of The University Of Michigan | Aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker |
US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
US8129183B2 (en) | 2006-10-31 | 2012-03-06 | Gaetano Finocchiaro | Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours |
WO2008052740A3 (en) * | 2006-10-31 | 2008-06-26 | Fond I R C C S Istituto Neurol | Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours |
US8293252B2 (en) | 2006-12-20 | 2012-10-23 | Novarx Corporation | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
EP2404614A1 (en) * | 2006-12-20 | 2012-01-11 | Novarx | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
AU2007347689B2 (en) * | 2006-12-20 | 2013-08-15 | Novarx | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
US9617340B2 (en) | 2007-01-24 | 2017-04-11 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
US8460661B2 (en) | 2007-01-24 | 2013-06-11 | Oncomed Pharmaceuticals, Inc. | Methods of using antibodies that bind the glutamate ligand binding region of Notch1 |
US8088617B2 (en) | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
US8921106B2 (en) | 2007-01-24 | 2014-12-30 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of NOTCH3 |
US9040044B2 (en) | 2007-07-02 | 2015-05-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8158757B2 (en) | 2007-07-02 | 2012-04-17 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US9717794B2 (en) | 2007-07-02 | 2017-08-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
EP3009148A1 (en) | 2007-07-02 | 2016-04-20 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8628774B2 (en) | 2007-07-02 | 2014-01-14 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
EP3424529A1 (en) | 2007-07-02 | 2019-01-09 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US9610348B2 (en) | 2007-07-02 | 2017-04-04 | Oncomed Pharmaceuticals, Inc | Compositions and methods for treating and diagnosing cancer |
US8883736B2 (en) | 2007-07-02 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8158758B2 (en) | 2007-07-02 | 2012-04-17 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8540989B2 (en) | 2007-07-02 | 2013-09-24 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8945547B2 (en) | 2008-07-08 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Notch1 receptor antibodies and methods of treatment |
US8945873B2 (en) | 2008-07-08 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Polynucleotides encoding Notch receptor antibodies |
US8435513B2 (en) | 2008-07-08 | 2013-05-07 | Oncomed Pharmaceuticals, Inc. | NOTCH1 receptor antibodies and methods of treatment |
US8980260B2 (en) | 2008-07-08 | 2015-03-17 | Oncomed Pharmaceuticals, Inc. | Monoclonal antibody that binds human notch2 and notch3 |
US8945874B2 (en) | 2008-07-08 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Polynucleotides encoding NOTCH1 receptor antibodies |
US9499613B2 (en) | 2008-07-08 | 2016-11-22 | Oncomed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
US8425903B2 (en) | 2008-07-08 | 2013-04-23 | Oncomed Pharmaceuticals, Inc. | Methods of treatment by administering antibodies to notch receptors |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US9505832B2 (en) | 2008-07-08 | 2016-11-29 | Oncomed Pharmaceuticals, Inc. | Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3 |
US8226943B2 (en) | 2008-07-08 | 2012-07-24 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EP2318040A4 (en) * | 2008-07-24 | 2013-05-01 | Univ Central Florida Res Found | Therapy targeting cancer stem cells |
EP2318040A1 (en) * | 2008-07-24 | 2011-05-11 | University Of Central Florida Research Foundation, Inc. | Therapy targeting cancer stem cells |
US8507442B2 (en) | 2008-09-26 | 2013-08-13 | Oncomed Pharmaceuticals, Inc. | Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8 |
US8975044B2 (en) | 2008-09-26 | 2015-03-10 | Oncomed Pharmaceuticals, Inc. | Polynucleotides encoding for frizzled-binding agents and uses thereof |
US9273139B2 (en) | 2008-09-26 | 2016-03-01 | Oncomed Pharmaceuticals, Inc. | Monoclonal antibodies against frizzled |
US9573998B2 (en) | 2008-09-26 | 2017-02-21 | Oncomed Pharmaceuticals, Inc. | Antibodies against human FZD5 and FZD8 |
US9982042B2 (en) | 2009-10-16 | 2018-05-29 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
US10870693B2 (en) | 2009-10-16 | 2020-12-22 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
US9511139B2 (en) | 2009-10-16 | 2016-12-06 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent |
US11536713B2 (en) | 2009-12-25 | 2022-12-27 | Chugai Seiyaku Kabushiki Kaisha | Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein |
US9157904B2 (en) | 2010-01-12 | 2015-10-13 | Oncomed Pharmaceuticals, Inc. | Wnt antagonists and methods of treatment and screening |
US9579361B2 (en) | 2010-01-12 | 2017-02-28 | Oncomed Pharmaceuticals, Inc. | Wnt antagonist and methods of treatment and screening |
US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US9499630B2 (en) | 2010-04-01 | 2016-11-22 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
US8551789B2 (en) | 2010-04-01 | 2013-10-08 | OncoMed Pharmaceuticals | Frizzled-binding agents and their use in screening for WNT inhibitors |
US9480744B2 (en) | 2010-09-10 | 2016-11-01 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US11124773B2 (en) | 2010-10-06 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell population and method for production thereof |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
US9644034B2 (en) | 2011-07-15 | 2017-05-09 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO2 antibodies and uses thereof |
US9109024B2 (en) | 2011-07-15 | 2015-08-18 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies and uses thereof |
US9109025B2 (en) | 2011-07-15 | 2015-08-18 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO2 antibodies |
US10018630B2 (en) | 2011-09-07 | 2018-07-10 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
US9376488B2 (en) | 2011-09-23 | 2016-06-28 | Oncomed Pharmaceuticals, Inc. | VEGF binding antibodies |
US10730940B2 (en) | 2011-09-23 | 2020-08-04 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US11512128B2 (en) | 2011-09-23 | 2022-11-29 | Mereo Biopharma 5, Inc. | VEGF/DLL4 binding agents and uses thereof |
US9879084B2 (en) | 2011-09-23 | 2018-01-30 | Oncomed Pharmaceuticals, Inc. | Modified immunoglobulin molecules that specifically bind human VEGF and DLL4 |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US9574009B2 (en) | 2011-09-23 | 2017-02-21 | Oncomed Pharmaceuticals, Inc. | Polynucleotides encoding VEGF/DLL4 binding agents |
US10934351B2 (en) | 2011-10-28 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
EP3603671A3 (en) * | 2011-10-28 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
US11858987B2 (en) | 2011-10-28 | 2024-01-02 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
EP2772268A4 (en) * | 2011-10-28 | 2015-12-02 | Chugai Pharmaceutical Co Ltd | Cancer stem cell-specific molecule |
US9598497B2 (en) | 2012-07-13 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
US9181333B2 (en) | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
US11524950B2 (en) | 2012-08-09 | 2022-12-13 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US10919883B2 (en) | 2012-08-09 | 2021-02-16 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US11183269B2 (en) | 2012-10-09 | 2021-11-23 | Five3 Genomics, Llc | Systems and methods for tumor clonality analysis |
US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US9987357B2 (en) | 2013-02-04 | 2018-06-05 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a WNT pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US11660302B2 (en) | 2014-05-19 | 2023-05-30 | Celgene Corporation | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
US10980812B2 (en) | 2014-05-19 | 2021-04-20 | Celgene Corporation | 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
US10596179B2 (en) | 2014-05-19 | 2020-03-24 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
US10064937B2 (en) | 2014-09-16 | 2018-09-04 | Oncomed Pharmaceuticals, Inc. | Treatment of dermal fibrosis |
US9969812B2 (en) | 2015-04-16 | 2018-05-15 | Eisai R&D Management Co., Ltd. | Anti human Notch4 antibody |
US9527921B2 (en) | 2015-04-16 | 2016-12-27 | Eisai R&D Management Co., Ltd. | Anti human Notch4 antibody |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
WO2018127055A1 (en) * | 2017-01-04 | 2018-07-12 | Yang Pan Chyr | Biomarkers for lung cancer stem cells |
CN110487998A (en) * | 2019-08-13 | 2019-11-22 | 迈克医疗电子有限公司 | Parameter optimization method and device, analysis instrument, the storage medium of magnetic separation system |
CN114787381A (en) * | 2019-12-12 | 2022-07-22 | 阿基里斯治疗英国有限公司 | Method for obtaining nucleic acids for sequencing |
WO2021116714A1 (en) * | 2019-12-12 | 2021-06-17 | Achilles Therapeutics Uk Limited | Method for obtaining nucleic acid for sequencing |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10227567B2 (en) | Isolation and use of solid tumor stem cells | |
US8044259B2 (en) | Determining the capability of a test compound to affect solid tumor stem cells | |
AU2001278134A1 (en) | Isolation and use of solid tumor stem cells | |
US8357491B2 (en) | Isolation and use of solid tumor stem cells | |
Shehata et al. | Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland | |
US20070220621A1 (en) | Genetic characterization and prognostic significance of cancer stem cells in cancer | |
Farabaugh et al. | IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis | |
AU2008200133B2 (en) | Isolation and use of solid tumor stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001278134 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2417909 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002517738 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001956101 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
B | Later publication of amended claims |
Free format text: 20030121 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10343692 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001956101 Country of ref document: EP |